WallStreetZenWallStreetZen

NASDAQ: ADAP
Adaptimmune Therapeutics PLC Earnings & Revenue

OverviewForecastEarnings
DividendOwnership

ADAP past revenue growth

How has ADAP's revenue growth performed historically?
Company
99.9%
Industry
76.88%
Market
16.68%
ADAP's revenue has grown slower... subscribe to Premium to read more.
Revenue Growth vs Industry Performance
ADAP's revenue has grown faster... subscribe to Premium to read more.
Revenue Growth vs Market Performance
ADAP's revenue growth is accelerating... subscribe to Premium to read more.
Accelerating Revenue Growth Performance

ADAP earnings and revenue history

Current Revenue
$141.5M
Current Earnings
-$72.5M
Current Profit Margin
-51.3%

ADAP Return on Equity

Current Company
-116.8%
Current Industry
23.1%
Current Market
34.1%
ADAP's Return on Equity (-116.8%)... subscribe to Premium to read more.
High Return on Equity Performance

Be the first to know when ADAP announces earnings.

ADAP Return on Assets

Current Company
-25%
Current Industry
3.6%
ADAP is generating lower Return... subscribe to Premium to read more.
Above Average Return on Assets Performance

ADAP Return on Capital Employed

Current Company
-29.58%
Current Industry
21.5%
ADAP has gotten more efficient... subscribe to Premium to read more.
Increasing Return on Capital Employed Performance

ADAP vs Biotech Stocks

TickerRevenueEBITDAEarningsY/Y RevenueY/Y Earnings
ADAP$141.46M-$59.56M-$72.50M+27.23%N/A
RNAC$54.10M-$244.51M-$233.86M+125.59%N/A
JSPR$0.00-$60.84M-$62.44MN/AN/A
AKBA$174.50M$11.86M-$40.44M-9.44%N/A
HRTX$136.36M-$44.85M-$48.13M+3.13%N/A
View Top Biotech Stocks

Adaptimmune Therapeutics Earnings & Revenue FAQ

What were ADAP's earnings last quarter?

On Invalid Date, Adaptimmune Therapeutics (NASDAQ: ADAP) reported Q2 2024 earnings per share (EPS) of $0.30, up 350% year over year. Total Adaptimmune Therapeutics earnings for the quarter were $69.52 million. In the same quarter last year, Adaptimmune Therapeutics's earnings per share (EPS) was -$0.12.

If you're new to stock investing, here's how to buy Adaptimmune Therapeutics stock.

What was ADAP's earnings growth in the past year?

As of Q3 2024, Adaptimmune Therapeutics's earnings has grown year over year. Adaptimmune Therapeutics's earnings in the past year totalled -$72.50 million.

What was ADAP's revenue last quarter?

On Invalid Date, Adaptimmune Therapeutics (NASDAQ: ADAP) reported Q2 2024 revenue of $128.23 million up 2,399.63% year over year. In the same quarter last year, Adaptimmune Therapeutics's revenue was $5.13 million.

What was ADAP's revenue growth in the past year?

As of Q3 2024, Adaptimmune Therapeutics's revenue has grown 99.9% year over year. This is 23.01 percentage points higher than the US Biotechnology industry revenue growth rate of 76.88%. Adaptimmune Therapeutics's revenue in the past year totalled $141.46 million.
©2024 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.